Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma

Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma

Abstract IMBrave 150 established atezolizumab and bevacizumab as the new standard for advanced hepatocellular carcinoma (HCC) treatment. However, the trial reported significant adverse events leading to bevacizumab dose interruptions or discontinuations. This retrospective, real-world analysis evalu...

Full description

Saved in:
Bibliographic Details
Main Authors: Dimity Ball, Jean-Charles Nault, Mathew Vithayathil, Manon Allaire, Nathalie Ganne-Carrié, Claudia Campani, Fabio Marra, Rohini Sharma
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-025-00908-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items